The US FDA has for several years published recommended guidelines for maximum tablet size for makers of dietary supplements. Though non-binding in nature, these guidelines were developed through extensive research on tablet size and shape, and the ages of individuals taking the supplements. Perhaps not all that surprising is that older adults were more sensitive to tablet size than others1. Since glucosamine is typically taken for joint pain and to address the effects of osteoarthritis this is especially relevant to our customers. Keeping to, or exceeding these guidelines offers a competitive advantage for any supplement manufacturer. Companies not only have to make sure their products contain enough active ingredients to deliver the desired dosages, they also have to meet the demand for more diverse and complex matrices in order to keep up with consumer trends.
TSI Group is focused on helping these companies achieve this competitive advantage. We’ve cracked the code on ideal glucosamine granule which can reduce tablet sizes by up to 20% based on the reduced need for binders and excipients. This can be done without compromising tablet hardness and ultimately tablet quality. Full FDA guideline can be found here.
1 Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements. N Engl J Med 2015;373(16):1531–40.